ImmuCell Corporation (NASDAQ:ICCC) Short Interest Update

ImmuCell Corporation (NASDAQ:ICCC) was the recipient of a significant decline in short interest in April. As of April 15th, there was short interest totaling 27,130 shares, a decline of 20.8% from the March 31st total of 34,248 shares. Approximately 0.3% of the company’s stock are short sold. Based on an average daily volume of 33,432 shares, the short-interest ratio is presently 0.8 days.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. Mesirow Financial Investment Management Inc. grew its holdings in ImmuCell by 199.6% during the 4th quarter. Mesirow Financial Investment Management Inc. now owns 36,481 shares of the biotechnology company’s stock worth $224,000 after acquiring an additional 24,303 shares in the last quarter. Steadtrust LLC lifted its position in shares of ImmuCell by 79.1% during the 4th quarter. Steadtrust LLC now owns 56,770 shares of the biotechnology company’s stock worth $349,000 after buying an additional 25,070 shares during the last quarter. Finally, Geode Capital Management LLC lifted its position in shares of ImmuCell by 4.2% during the 2nd quarter. Geode Capital Management LLC now owns 71,852 shares of the biotechnology company’s stock worth $500,000 after buying an additional 2,907 shares during the last quarter. Institutional investors and hedge funds own 13.47% of the company’s stock.

ImmuCell Stock Up 3.2%

NASDAQ ICCC traded up $0.27 on Friday, hitting $8.73. 18,043 shares of the stock were exchanged, compared to its average volume of 27,300. The company has a current ratio of 4.26, a quick ratio of 1.93 and a debt-to-equity ratio of 0.28. ImmuCell has a fifty-two week low of $4.52 and a fifty-two week high of $8.82. The company has a 50-day moving average price of $6.89 and a 200-day moving average price of $6.31.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings cut shares of ImmuCell from a “hold (c-)” rating to a “sell (d-)” rating in a report on Monday, April 6th. One investment analyst has rated the stock with a Sell rating, According to MarketBeat.com, ImmuCell has a consensus rating of “Sell”.

About ImmuCell

ImmuCell Corporation (NASDAQ: ICCC) is a biotechnology company that develops, manufactures, and markets immunological products and diagnostic assays designed to enhance animal health in dairy and beef cattle. Headquartered in Portland, Maine, the company focuses on supporting herd health management through its portfolio of passive immunology solutions and veterinary diagnostics.

The company’s flagship offering, CalfGuard natural colostrum supplement, is formulated to promote the passive transfer of antibodies in newborn calves and reduce the incidence of neonatal diseases.